GSK plc — FY 2022 Form 20-F
Reporting period: Year ended December 31, 2022; filed March 10, 2023. This is an annual report, not a stand-alone Q4 filing. Financial statements are prepared under IFRS as issued by the IASB. Unless otherwise noted, amounts are in pounds sterling and comparatives are presented on a restated basis following the Consumer Healthcare demerger and share consolidation.
Business context and key performance
Following the July 18, 2022 demerger of Consumer Healthcare, GSK operates as a biopharmaceutical company focused on specialty medicines, vaccines and general medicines. The filing reports two segments: Commercial Operations and Total R&D.
| Metric | FY 2022 | Comparison / context |
|---|---|---|
| Turnover | £29.324bn | Up 19% at actual exchange rates (AER) and 13% at constant exchange rates (CER). |
| Total operating profit, continuing operations | £6.433bn | 2021: £4.357bn; up 48% AER and 31% CER. |
| Adjusted operating profit | £8.151bn | 2021: £6.493bn; up 26% AER and 14% CER. |
| Operating margins | Total: 21.9%; adjusted: 27.8% | Adjusted margin was up 1.5 percentage points AER and 0.3 points CER. |
| Profit after tax, continuing operations | £4.921bn | 2021: £3.516bn. |
| Adjusted profit after tax / adjusted EPS | £6.220bn / 139.7p | Adjusted EPS was up 27% AER and 15% CER from 110.3p. |
| Total profit after tax / total EPS | £15.621bn / 371.4p | Includes £10.7bn profit from discontinued operations, substantially reflecting the demerger; not representative of continuing earnings. |
| Cash from continuing operations / free cash flow | £7.944bn / £3.348bn | Cash from operations rose from £7.249bn; free cash flow rose from £3.301bn. |
| Net debt | £17.197bn | Down from £19.838bn; gross debt £21.0bn and cash and liquid investments £3.8bn. |
Revenue mix and material changes
- Specialty Medicines: £11.269bn, up 37% AER and 29% CER. Xevudy contributed £2.309bn; excluding Xevudy, specialty sales were £8.960bn, up 23% AER and 15% CER. HIV, immunology and respiratory products also grew.
- Vaccines: £7.937bn, up 17% AER and 11% CER, led by Shingrix (£2.958bn, up 72% AER and 60% CER) and meningitis vaccines. Pandemic vaccine/adjuvant sales fell sharply against the prior-year comparator.
- General Medicines: £10.118bn, up 5% AER and 1% CER. Trelegy and the recovery in antibiotic demand offset generic competition.
- COVID-19 solutions contributed approximately 3 percentage points to commercial turnover growth. Low-margin Xevudy sales weighed on adjusted operating profit growth and margin.
- The Gilead settlement generated $1.25bn upfront for ViiV Healthcare, recognised as approximately £922m of income, plus a 3% royalty on specified US sales through October 2027.
Cash, debt, liquidity and distributions
- Free cash flow was £3.348bn. Management cited higher operating profit and favorable collections, partly offset by Xevudy profit-share payments, pension contributions, contingent consideration payments, tax, capital expenditure and inventory growth.
- Net debt declined by £2.6bn, reflecting free cash flow and the demerger-related reduction in debt, partly offset by acquisitions, shareholder dividends and adverse currency effects. Borrowings were £20.1bn; £3.8bn was repayable within one year.
- GSK stated it had sufficient working capital for present requirements and expected long-term operating cash generation to fund operating costs, debt service, normal capital expenditure and routine obligations, subject to principal risks.
- FY 2022 dividends totaled 61.25p per share after the share consolidation, compared with 100p in 2021. The stated policy is a progressive dividend guided by a 40%–60% payout ratio through the investment cycle; the filing cites an expected 2023 dividend of 56.5p per new ordinary share.
Outlook, commentary and risks
- Based on known government contracts, GSK did not anticipate significant COVID-19 pandemic-related sales or operating profit in 2023. It expected this to reduce turnover growth by about 9% and adjusted operating profit growth by 6%–7% versus the comparison base; further variant-related opportunities remained uncertain.
- Management linked adjusted earnings growth to sales, mix, lower inventory adjustments and higher royalty income, while noting increased launch investment, supply-chain, freight and distribution costs, and higher non-controlling interests.
- Key exposures include product safety and quality, regulatory compliance, litigation and investigations, research and clinical-development execution, commercial and pricing pressure, data privacy and cybersecurity, supply continuity, inflation, foreign exchange and tax uncertainty.
- Climate risks include extreme weather and water stress affecting supply, evolving environmental rules and costs, and the need for successful R&D and regulatory approval to reduce emissions from metered-dose inhalers.
- The demerger leaves GSK smaller and less diversified, with greater exposure to pharmaceuticals and vaccines; the value of its retained Haleon investment is subject to market movements. GSK retained a 6.0% holding, while Scottish limited partnerships held 7.5% to support UK pension funding.
- Legal matters include product-liability, patent, antitrust and other disputes. The auditor identified Zantac litigation as a significant legal matter; the reported provision for legal and other disputes was £218m, but potential outcomes and any additional exposure were not reliably estimable from the disclosed information.
- The auditor highlighted estimation uncertainty in the £5.890bn ViiV-Shionogi contingent consideration liability, US returns-and-rebates accruals, intangible-asset valuations, uncertain tax positions and the Consumer Healthcare demerger. Management and Deloitte reported effective internal control over financial reporting; the financial-statement audit opinion was unqualified.
Important facts for investors to verify
- Separate recurring continuing-operations performance from the demerger gain, Gilead settlement income, fair-value movements and other adjusting items; reconcile total and adjusted results.
- Assess how much 2022 growth depended on Xevudy, pandemic-related sales and the Gilead payment, and compare with the stated 2023 COVID-related headwinds.
- Review assumptions behind ViiV contingent consideration, including product sales forecasts, discounting and cash payments, and the £1.093bn Pfizer put-option liability.
- Track US rebates and returns estimates, tax disputes, Zantac and other legal proceedings, and any changes to provisions or contingent exposures.
- Confirm debt maturities, acquisition-related obligations, milestone commitments and pension funding needs; the disclosed £10.659bn intangible-asset commitments are maximum potential milestone amounts, not risk-adjusted forecasts.
- Evaluate dividend sustainability against free cash flow, investment needs and the post-demerger business profile; review the retained Haleon stake and related pension-funding arrangements.